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ABSTRACT
Introduction & objectives Adaptive deep brain
stimulation (aDBS) uses feedback from brain signals to
guide stimulation. A recent acute trial of unilateral aDBS
showed that aDBS can lead to substantial improvements
in contralateral hemibody Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) motor scores and may be superior
to conventional continuous DBS in Parkinson’s disease
(PD). We test whether potential beneﬁts are retained
with bilateral aDBS and in the face of concurrent
medication.
Methods We applied bilateral aDBS in 4 patients with
PD undergoing DBS of the subthalamic nucleus. aDBS
was delivered bilaterally with independent triggering of
stimulation according to the amplitude of β activity at
the corresponding electrode. Mean stimulation voltage
was 3.0±0.1 volts. Motor assessments consisted of
double-blinded video-taped motor UPDRS scores that
included both limb and axial features.
Results UPDRS scores were 43% (p=0.04; Cohen’s
d=1.62) better with aDBS than without stimulation.
Motor improvement with aDBS occurred despite an
average time on stimulation (ToS) of only 45%.
Levodopa was well tolerated during aDBS and led to
further reductions in ToS.
Conclusion Bilateral aDBS can improve both axial and
limb symptoms and can track the need for stimulation
across drug states.
INTRODUCTION
Deep brain stimulation (DBS) is an established
treatment for advanced Parkinson’s disease (PD).1
However, its applicability is limited by costs, side
effects and partial efﬁcacy.2 That symptoms ﬂuctu-
ate based on cognitive/motor load, stress and medi-
cation status in PD is well established.3 Increasing
evidence suggests that these ﬂuctuations are asso-
ciated with varying levels of subcortical β (13–
30 Hz) oscillations, changes in the amplitude of
which correlate with motor improvement in
response to treatment.4–7 Building on a pioneering
adaptive DBS (aDBS) study in the parkinsonian
non-human primate,8 we recently successfully
applied aDBS to patients with PD by triggering
stimulation off the amplitude of β activity in the
local ﬁeld potential (LFP) recorded from the sub-
thalamic nucleus (STN).9 This study showed that
aDBS was more effective than continuous DBS
(cDBS) despite <50% of the total time on stimula-
tion (ToS). However, aDBS was applied unilaterally,
with only 5 min stimulation and no assessment of
axial symptoms nor control in different drug states.
Bilateral stimulation is essential if aDBS is to be
progressed towards clinical applicability. However,
this presents technical challenges. Although the
subcortical β network is signiﬁcantly coherent bilat-
erally,10 levels of amplitude co-modulation and
phase synchronisation between STNs are low.11
This suggests that bilateral aDBS may require inde-
pendent sensing and stimulating. We tested the efﬁ-
cacy of bilateral aDBS in PD, using independent
bilateral sensing and stimulation, and in two
patients we assessed how aDBS responded to levo-
dopa administration.
PATIENTS AND METHODS
We tested four male patients with advanced idio-
pathic PD undergoing DBS of the STN (table 1).
All patients gave their informed written consent
(approved by the local ethics committee). Patients
underwent surgery in a two-stage procedure with
bilateral quadripolar Medtronic (3389) electrode
placement and stimulator implantation separated by
1 week, as previously described.9 12 All testing was
performed 2–6 days after electrode implantation.
We recorded bipolar LFP activity from the STN
electrode contacts after overnight withdrawal of
anti-parkinsonian medication. Recordings were
made using a band-pass (3–37 Hz) ampliﬁer that
has been previously described.9 13 However, in this
experiment, the ampliﬁer and stimulator independ-
ently served both hemispheres and was minia-
turised, ﬁxed to the patient on their belt and
connected to the base unit by a 10 m cable allowing
assessment of ambulation and axial signs.
Bipolar recordings were made from the contact
pair (0–2 or 1–3) exhibiting the greatest β ampli-
tude determined for each hemisphere in the
unstimulated and OFF-medication state. We then
determined a single-centre frequency and band-
width which encompassed both of these peaks and
set this for our second stage of ﬁltering (table 1).
Online β amplitudes were obtained by rectifying
and smoothing (400 ms moving average) the ﬁl-
tered LFP for each hemisphere. β Amplitude was
then used to control triggering of stimulation via a
user-deﬁned threshold through a portable com-
puter for each side independently.9 Stimulation was
delivered by a dual version of our previously
described stimulator.9 On triggering, stimulation
was sustained until β amplitude fell below threshold
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(ﬁgure 1). Stimulation pulses were charge-balanced, monopolar
and symmetrically biphasic (130 Hz, pulse width 100 ms, anodal
pulse ﬁrst then a 20 ms delay before the balancing cathodal
pulse). An impedance of 0.5 kΩ was assumed for calculation of
total electrical energy.
The stimulation voltage was determined during aDBS. The
voltage was adjusted, along with the β amplitude trigger thresh-
old, aiming for clinical beneﬁt without paraesthesia, and a total
ToS of approximately 50%.9 The contact selected for stimula-
tion was that which lay between the contacts used for record-
ing.13 Stimulation begun at 0.5 V and was increased by 0.1 V
increments in order to reach a clinically effective voltage as
determined by repeat assessments of rigidity and ﬁnger tapping
by the attending (unblinded) neurologist. This voltage was then
taken forward for formal testing and blinded assessment.
Voltage testing was performed separately, leading to two inde-
pendent stimulation voltages (table 1). Patients were clinically
assessed during aDBS and no stimulation. The order of
experimental conditions was randomised. We compromised on
a 5 min washout period between conditions so as to ensure the
acceptability of the experimental session which then lasted
about 1.5 h in two patients and 2.5 h in those two patients that
went on to be stimulated during a levodopa treatment cycle.
Stimulation (or no stimulation) was given for 15 min and clin-
ical testing performed thereafter. In between experimental con-
ditions, we tested the patients to conﬁrm return to baseline
before the next condition as judged through ﬁnger tapping.
Our primary outcome measure was the motor Uniﬁed
Parkinson’s Disease Rating Scale Part III (UPDRS III)14 with
aDBS compared with no stimulation. Our secondary outcomes
were power saving expressed as mean total electrical energy
delivered with aDBS compared with similar, hypothetical, con-
tinuous stimulation and the correlation between β power and
ToS. The patients were blinded by being kept unaware of the
stimulation conditions throughout the experiment. In particular,
the patients did not experience paraesthesia during aDBS.
Table 1 Clinical and stimulation details of patients
Patient 1 Patient 2 Patient 3 Patient 4 Mean+SEM
Age (years) 66 41 52 54 53.3±5.1
Disease duration (years) 6 7 8 25 11.5±4.5
Preoperative UPDRS off-drugs 49 50 40 32 42.8±4.2
Preoperative UPDRS on-drugs 19 21 11 4 13.8±3.9
Surgery location Oxford London London London
Initial symptom Tremor Bradykinesia Tremor Rigidity
Primary DBS indication Refractory tremor ON-OFF fluctuations Severe OFF states OFF-related dystonia
Preoperative drugs (mg/day) Levodopa 1000
Pramipexole 3.15
Levodopa 625
Amantadine 100
Levodopa 500 Rotigotine 4 Levodopa 1600
Pramipexole 0.375
Tolcapone 800
Online digital filter range (Hz) 20±3 21±3 25±3 20±6 21.5±0.8
Stimulation voltage (V, L/R) 3.4/3.4 3.4/3.3 2.5/2.4 3.0/3.0 3.0±0.1
aDBS ToS (%, L/R) 25/38 53/52 35/36 62/60 45.0±4.8
aDBS, adaptive deep brain stimulation; L, left; R, right; SEM, SE of the mean; ToS, time on stimulation; UPDRS, Unified Parkinson’s Disease Rating Scale Part III (motor).
Figure 1 Screen shot of 15 s bilateral adaptive deep brain stimulation (aDBS) in patient 1. Bottom two traces are local ﬁeld potentials (LFPs) after
ﬁrst stage analogue ﬁltering (LFPf1; 3–37 Hz). Third and fourth traces from bottom show LFPs after second stage digital ﬁltering around patient
speciﬁc β peak (LFPf2; 20±3 Hz). The two traces above are the online readouts of the ﬁltered β amplitude after rectiﬁcation, smoothing and
thresholding. The top two traces show bursts of ramped stimulation in response to β amplitude threshold crossing. Blue and red traces are from left
and right electrodes, respectively. Note stimulation across the two sides is discontinuous and independent.
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Although patients do sometimes experience paraesthesia during
conventional DBS, the latter delivers more than twice the elec-
trical energy used here. Bursts of stimulation during the aDBS
practised here were short-lived, ramped in onset and offset and,
on average, interspersed by periods of non-stimulation for 55%
of the time (see table 1). UPDRS III assessments were also
blinded by videoing them and having the videos rated (rigidity
items excluded) by two external movement disorders specialists
who were not involved in the experiment and were also
unaware of the experimental conditions. There was strong con-
cordance between the two raters with only an 11% average
absolute difference between matched scores (p=0.85). UPDRS
III scores were further divided into limb bradykinesia (items 8–
17) and axial symptoms (arise from chair (18), gait (19), stabil-
ity (21), posture (22) and overall bradykinesia (23)). Unblinded
rigidity assessments were also reported separately for both
experimental conditions.
Clinical data are described using means and SE of means,
were normally distributed (Kolmogorov-Smirnov test, p>0.05)
and analysed using two-sided t tests (t statistics with degrees of
freedom shown along with p values). The ﬁrst part of each
recording during which the stimulation threshold was heuristic-
ally determined and any periods with marked electrical artefacts
were excluded. We analysed the ﬁrst (concatenated if necessary)
section of 10 min artefact-free data after a stable threshold was
obtained in each participant. Spectral analysis was conducted
using Welch’s method with a Hamming window (1 s). β Power
and ToS were averaged over non-overlapping 10 s blocks and
normalised to the average value of the ﬁrst minute. To analyse
the within-participant relation between mean β power per 10 s
and total time on aDBS, between ToS per 10 s and total time on
aDBS, and between ToS and β power per 10 s Spearman’s corre-
lations were estimated. Correlation coefﬁcients were Fisher
transformed, averaged and back-transformed. In patients 3 and
4, we performed additional, prolonged recordings of 45 and
60 min duration, respectively. At the beginning of these record-
ings, 100 mg levodopa was administered and the patients
reported a transition from a clinical OFF to ON state which was
conﬁrmed by clinical examination of rigidity and bradykinesia.
We performed change-point analysis to objectively identify
when there was a simultaneous change in the ToS.
Change-point analysis iteratively uses a combination of time-
varying cumulative sum charts and bootstrapping to detect
changes in time series.15 To avoid violation of the independent
errors assumption, ToS was averaged over successive groups of
three data points (where each data point was the average ToS
over 10 s). Ten thousand bootstraps were performed in each test
and only changes with probabilities of >99% shown. Signiﬁcant
changes in signal were depicted by means of different conﬁ-
dence limits. In one of the two patients (patient 4) a formal
UPDRS III was performed, videoed and blindly rated during the
levodopa challenge.
RESULTS
Clinical effect
The mean UPDRS part III score OFF medication without stimu-
lation in the days following surgery was 33.5±5.4 in the four
patients. Individual and group data are illustrated in ﬁgure 2.
There was a substantial improvement with aDBS in every par-
ticipant (43% reduction: t3=3.24, p=0.04; Cohen’s d=1.62).
For limb bradykinesia and axial symptoms, the reductions were
37±10% and 39±5%, respectively. Remaining items, including
tremor, speech, facial expression and freezing, improved by
55±12%. Unblinded rigidity scores were 9.5±1.5 in the condi-
tion without stimulation and 6.4±0.55 in the aDBS condition.
Power savings
Total ToS for the whole stimulation period of aDBS was
45±4.8% averaged over the eight sides (4 subjects).
Furthermore, LFP β amplitude and ToS tended to drop during
the ﬁrst 10 min. This was evidenced by the negative correlation
between mean β power and total time on aDBS, and mean ToS
and total time on aDBS across the eight sides. For β, the average
Spearman’s correlation coefﬁcient was −0.23±0.08 (single
sample t test, p=0.02). For ToS, the average Spearman’s correl-
ation coefﬁcient was −0.20±0.15 (p=0.21). The mean total
electrical energy delivered with aDBS was 223±31 mW.
Conventional continuous stimulation at the same voltage would
have delivered 491±44 mW.
Response to levodopa
A prolonged recording following administration of levodopa
medication in patient 3 resulted in a self-reported clinical effect
30 min after ingestion when the average ToS also signiﬁcantly
dropped (ﬁgure 3). In the prolonged recording in patient 4, a
clinical effect was seen 40 min after levodopa. Again, the
average ToS signiﬁcantly dropped at this point (ﬁgure 3).
Importantly, this drop in ToS occurred without deterioration in
motor state, which instead improved from a blinded video-rated
UPDRS III score of 17.5 with aDBS OFF drug, to 6.5 on aDBS
and levodopa. The blinded video rating of items 1–8 of the
Abnormal Involuntary Movement Scale was 1 out of 50. Note
that on both sides of the two patients, change-point analysis of
the ToS per 10 s was able to independently identify when
patients turned ON after medication. Change point analysis of
ToS (ﬁgure 3) also suggested that the progressive drop in β
power and ToS seen at the very outset of aDBS plateaued with
continued aDBS.
Beta tracking
β Power showed a positive correlation with ToS in each par-
ticipant in each hemisphere. The average Spearman’s correl-
ation coefﬁcient was 0.62±0.12. In 7/8 hemispheres, this
correlation was signiﬁcant. In the recordings ON and OFF
drugs in patients 3 and 4 (4 hemispheres) similar, even
Figure 2 Group mean blinded UPDRS motor scores in the two
experimental conditions and their SEs. *Indicates signiﬁcance with
p<0.05. Red circles depict individual data. DBS, deep brain stimulation;
UPDRS, Uniﬁed Parkinson’s Disease Rating Scale.
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stronger, correlations were present. The average Spearman’s
correlation coefﬁcient for these recordings was 0.884±0.147
(4 hemispheres).
DISCUSSION
We have previously shown that acute unilateral aDBS improves
limb function more than unilateral cDBS.9 We demonstrate that
bilateral aDBS using two autonomous sensing-and-stimulate
systems is well tolerated and improves both axial and limb
motor function. The mean effect size was a 43% reduction in
blinded UPDRS scores relative to no stimulation and this was
substantial with respect to the variability in the sample, as deter-
mined by Cohen’s d. This large effect size of aDBS enabled stat-
istically signiﬁcant conclusions even though our sample was
small. Moreover, we found that aDBS was appropriately modu-
lated by levodopa administration, with a further reduction in
stimulation, potentially preventing excessive combined therapy
and dyskinesias. These ﬁndings suggest that bilateral aDBS may
prove a safe, effective and highly efﬁcient form of DBS in PD.
The scale of improvement with aDBS was striking, even
though stimulation was only on for 45% of the time, averaged
across the eight hemispheres. The latter is of critical importance
as it impacts on both side effects and the life time of implanted
battery systems. The 43% improvement with aDBS was similar
to that seen with unilateral aDBS,9 and similar to that achieved
with cDBS, when this has been similarly assessed through
blinded rating of videos in other studies.16–18 Such reports tend
to afford lower effect sizes than unblinded assessments, with
blinded cDBS improvement estimates ranging between 25% and
38% for assessments of chronic bilateral stimulation with
implanted systems16–18 and 31% with acute postoperative uni-
lateral cDBS.9
Several experimental limitations may have biased against the
detection of all but major effect sizes. Our sample size was small
and stimulation regimes were tested only a few days after elec-
trode implantation, when stun effects are present leading to
increased electrode impedances and temporary improvement in
baseline impairments.19–21 The presence of a stun effect in our
sample was evidenced by the difference between the mean
OFF-medication OFF-stimulation UPDRS score in the days fol-
lowing surgery (33.5±5.4, see Results section) and that
recorded preoperatively (42.8±4.2, see table 1). We were also
restricted to stimulating one of the middle two contacts of the
implanted electrode on each side. Finally, there may have been
incomplete washout between conditions. Although the rando-
mised presentation of conditions should have ameliorated this
in so far as incomplete washout should apply to both condi-
tions, this cannot be relied on with a small sample, such as in
this study, where order effects may still be inﬂuential.
Furthermore, although the evidence suggests that the effects of
conventional cDBS at least, are substantially, but not completely
diminished after 5 min of washout, as used here,22–24 the time
course of washout for axial symptoms is longer and the time
course of the washout of aDBS is unknown. However, longer
washout periods would have risked making the experiment
unacceptably long for the immediate postoperative period.
Nevertheless, these different factors were insufﬁcient to obfus-
cate the large and signiﬁcant effect size of aDBS.
The possibility that bilateral aDBS may be effective despite a
mean ToS of 45% (with a comparable reduction in energy con-
sumption) may prove to have major advantages in limiting
stimulation side effects. Theoretical and empirical evidence sug-
gests that conventional DBS can involve direct spread to local
ﬁbre tracts and interfere with physiological network activity and
thereby compromise motor skills, including speech.25 Although
current spread to ﬁbre tracts will still occur with aDBS, overall
side effects may potentially lessen as stimulation is more limited
in time and delivered only when β network activity is patho-
logically synchronised.26 This potential for side effect reduction
is underscored by the response of the stimulation system to levo-
dopa administration. Stimulation on time was signiﬁcantly
reduced, in response to β suppression with levodopa.4
Overall, this study demonstrates that bilateral aDBS is well toler-
ated, improves total motor UPDRS III scores, and yet requires on
average 45% of the standard ToS. The large effect size of aDBS
enabled statistically robust conclusions even though our sample
Figure 3 Per cent ToS during
prolonged aDBS after levodopa
administration at time 0 and its
dependency on β power. (A) Grey
blocks indicate the periods of stable
ToS as identiﬁed by change-point
analysis (p<0.01). The vertical extent
of the blocks denotes the conﬁdence
limits of blocks between signiﬁcant
change points and these blocks are
centred on the mean of the stable
period. The vertical arrows denote
when clinical improvement due to
levodopa was ﬁrst manifest. ToS
dropped at the onset of the clinical
effect of levodopa. Note that prior to
this, ToS was stable for about 30 min
or more, suggesting that the
progressive drop in ToS at the very
outset of aDBS plateaued with
continued aDBS. (B) Scatter plots of
β power and ToS per 10 s block. Grey
line is the product of linear regression.
aDBS, adaptive deep brain stimulation;
STN, subthalamic nucleus; ToS, time
on stimulation.
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was small. Since β LFP activity is a relatively consistent feature of
the STN in PD2 and consistent over long periods of time,21 27 this
approach has the potential to be realised clinically. However, much
work remains to be done to explore and optimise the full range of
parameters and algorithms that could be employed. Hereafter, the
next step will be a head-to-head comparison of aDBS with stand-
ard continuous high-frequency DBS, with voltages and other
stimulation parameters independently optimised for each stimula-
tion regime in a large patient cohort.
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